Evaluatie van het effect van ketanserin i.v. op de sublinguale microcirculatie middels SDF-imaging bij septische patienten op de Intensive Care

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2010-023767-18-NL

Enrollment

Registered

2011-01-13

Start date

2011-01-17

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

severe sepsis

Interventions

Product Name: Ketanserin Product Code: Asc-132 Pharmaceutical Form: Concentrate for solution for infusion

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ICU patients > 18 years with severe sepsis and MFI =65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: age < 18 participating in another clinical trial

Design outcomes

Primary

Measure	Time frame
Main Objective: Evaluation of the effect of ketanserin on sublingual microcirculation in intensive care unit (ICU) patients with severe sepsis;Secondary Objective: secondary goal of this study is obtaining a global indication of the ketanserin dosage needed to achieve a MFI . 2.9 and the incidence of hypotension. The other collected variables serve to describe the study population;Primary end point(s): achievement of a microvascular flow index (MFI) >2.9	—

Measure

Time frame

Main Objective: Evaluation of the effect of ketanserin on sublingual microcirculation in intensive care unit (ICU) patients with severe sepsis;Secondary Objective: secondary goal of this study is obtaining a global indication of the ketanserin dosage needed to achieve a MFI . 2.9 and the incidence of hypotension. The other collected variables serve to describe the study population;Primary end point(s): achievement of a microvascular flow index (MFI) >2.9

—

Countries

Netherlands

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026